Phase I and pharmacodynamic study of high-dose NGR–hTNF in patients with refractory solid tumours

BACKGROUND: NGR–hTNF exploits the peptide asparagine–glycine–arginine (NGR) for selectively targeting tumour necrosis factor (TNF) to CD13-overexpressing tumour vessels. Maximum-tolerated dose (MTD) of NGR–hTNF was previously established at 45 μg m(−2) as 1-h infusion, with dose-limiting toxicity be...

Descripción completa

Detalles Bibliográficos
Autores principales: Zucali, P A, Simonelli, M, De Vincenzo, F, Lorenzi, E, Perrino, M, Bertossi, M, Finotto, R, Naimo, S, Balzarini, L, Bonifacio, C, Timofeeva, I, Rossoni, G, Mazzola, G, Lambiase, A, Bordignon, C, Santoro, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3553515/
https://www.ncbi.nlm.nih.gov/pubmed/23169299
http://dx.doi.org/10.1038/bjc.2012.506

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3553515/
https://www.ncbi.nlm.nih.gov/pubmed/23169299
http://dx.doi.org/10.1038/bjc.2012.506

Ejemplares similares